Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Capital Leases (2016 - 2018)

Seres Therapeutics (MCRB) has disclosed Capital Leases for 4 consecutive years, with $6.8 million as the latest value for Q4 2018.

  • Quarterly Capital Leases fell 24.62% to $6.8 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2018, down 24.62% year-over-year, with the annual reading at $6.8 million for FY2018, 24.62% down from the prior year.
  • Capital Leases hit $6.8 million in Q4 2018 for Seres Therapeutics, down from $7.7 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $10.7 million in Q3 2016 to a low of $586000.0 in Q4 2015.
  • Historically, Capital Leases has averaged $8.1 million across 4 years, with a median of $9.0 million in 2017.
  • Biggest five-year swings in Capital Leases: soared 1731.06% in 2016 and later decreased 24.62% in 2018.
  • Year by year, Capital Leases stood at $586000.0 in 2015, then skyrocketed by 1731.06% to $10.7 million in 2016, then fell by 16.23% to $9.0 million in 2017, then decreased by 24.62% to $6.8 million in 2018.
  • Business Quant data shows Capital Leases for MCRB at $6.8 million in Q4 2018, $7.7 million in Q3 2018, and $8.1 million in Q2 2018.